NURIX THERAPEUTICS INC. - COMMON STOCK

Nurix Therapeutics Presents Data at the American Association for Cancer Research (AACR) Annual Meeting Highlighting Activity of its BTK Targeted Protein Degraders, NX-2127 and NX-5948, against a Broad Range of BTKi Resistance Mutations

17 4 2023 11:30:00 提供 Nasdaq GlobeNewswire

Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

13 4 2023 13:01:00 提供 Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference

11 4 2023 13:01:00 提供 Nasdaq GlobeNewswire

Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479

20 3 2023 05:30:00 提供 Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting

14 3 2023 13:45:08 提供 Nasdaq GlobeNewswire

Nurix Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

06 3 2023 13:01:00 提供 Nasdaq GlobeNewswire

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update

09 2 2023 13:15:00 提供 Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

08 2 2023 13:01:00 提供 Nasdaq GlobeNewswire

Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities

09 1 2023 05:35:39 提供 Nasdaq GlobeNewswire

Nurix Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

04 1 2023 04:01:00 提供 Nasdaq GlobeNewswire

Nurix Therapeutics Announces Clearance of Investigational New Drug Application for NX-5948 Supporting Plans to Expand Enrollment to U.S. Clinical Sites

15 12 2022 13:01:00 提供 Nasdaq GlobeNewswire

Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting

12 12 2022 14:30:00 提供 Nasdaq GlobeNewswire

Nurix Therapeutics Announces Webcast to Review Data from its Phase 1 Clinical Trial of BTK Degrader, NX-2127, Presented at the 64th American Society of Hematology Annual Meeting

07 12 2022 13:01:00 提供 Nasdaq GlobeNewswire

Nurix Announces DeTIL-0255 Scientific Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) and Successful Completion of DeTIL-0255 Phase 1 Safety Run-in

10 11 2022 06:00:02 提供 Nasdaq GlobeNewswire

Nurix Announces Initial NX-1607 Phase 1 Data Presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Demonstrating Targeted CBL-B Inhibition in Patients with Advanced Malignancies

10 11 2022 06:00:01 提供 Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentations at the 64th American Society of Hematology (ASH) Annual Meeting

03 11 2022 06:00:01 提供 Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

02 11 2022 13:01:00 提供 Nasdaq GlobeNewswire

Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit

26 10 2022 04:00:01 提供 Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentations at the 5th Annual Targeted Protein Degradation (TPD) Summit

19 10 2022 06:00:01 提供 Nasdaq GlobeNewswire

Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update

06 10 2022 13:01:00 提供 Nasdaq GlobeNewswire